Syngenta AG (SYT)

Plant Science generates some income through product sales of QUANTUM^® Phytase in Mexico, with registration in the United States awaited, and through outlicensing of technology. Syngenta expects future income to arise from new product development, licensing and other arrangements. To drive near term success, Plant Science has put emphasis on the commercialization of close-to-market projects that are aligned with the strengths of the Syngenta Crop Protection and Seeds businesses.

Plant Science generates some income through product sales of QUANTUM Phytase in Mexico, with registration in the United States awaited, and through outlicensing of technology. Syngenta expects future income to arise from new product development, licensing and other arrangements. To drive near term success, Plant Science has put emphasis on the commercialization of close-to-market projects that are aligned with the strengths of the Syngenta Crop Protection and Seeds businesses. Syngentas 2004 acquisitions of Garst and Golden Harvest to strengthen its business in the North American corn and soybean seed business and the licensing of biotechnology products for cotton to Delta and Pine Land Company are expected to increase the availability and penetration of Syngenta biotech traits when commercialized. Following the acquisitions, corn trait development activities have been transferred to the Seeds business as part of Field Crops, where future commercial benefits will be realized.

For the longer term, Syngenta is exploring opportunities in emerging areas of biotechnology such as enzymes and plant made pharmaceuticals. The latter has the potential to make the next generation of medicines more readily available to patients. Some of the Plant Science projects described here are within five years of commercial availability.